HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
--
--(--)
Halozyme Therapeutics (HALO) Financials Overview
Halozyme Therapeutics (HALO) released its earnings on Aug 6, 2026: revenue was 481.00M (YoY +47.67%), beat estimates; EPS was 2.28 (YoY +48.05%), beat estimates.
Revenue / YoY
481.00M
+47.67%
EPS / YoY
2.28
+48.05%
Report date
Aug 6, 2026
HALO Earnings Call Summary for Q2,2026
- Revenue Records: Q2 2026 total revenue $481M (+48% YoY), royalty revenue $308M (+50% YoY). Raised 2026 guidance to $1.835B-$1.91B total revenue.
- ENHANZE Expansion: 5 new deals ($35.5M upfront), entering ADCs and nucleic acids. 13 development programs by year-end.
- HyperCon Growth: 5 partnerships, 20+ targets, first clinical starts 2027. Projected $1B+ royalties in mid-2030s.
- Profitability: Adjusted EBITDA $329M (65% margin), Non-GAAP EPS $2.28. Free cash flow used for buybacks ($332.8M Q2) and R&D.
- Litigation: Active in 8+ countries against Merck's QLEX; U.S. PGR appeals expected to resolve by end-2026.
EPS
Revenue
Revenue & Expenses
HALO has released its 2026 Q2 earnings report, with revenue of 481.00M, reflecting a YoY change of 47.67%, and net profit of 229.91M, showing a YoY change of 39.21%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.
Key Indicators
Halozyme Therapeutics (HALO) key financial stats and ratios, covering profitability, financial health, and leverage.
Halozyme Therapeutics (HALO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Halozyme Therapeutics (HALO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Halozyme Therapeutics (HALO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
More Financial Metrics
You can ask Aime
What is the market's earnings forecast for Halozyme Therapeutics next quarter?What factors drove the changes in Halozyme Therapeutics's revenue and profit?What does Halozyme Therapeutics do and what are its main business segments?What were the key takeaways from Halozyme Therapeutics's earnings call?What guidance did Halozyme Therapeutics's management provide for the next earnings period?Did Halozyme Therapeutics beat or miss consensus estimates last quarter?What is Halozyme Therapeutics's gross profit margin?What were the key takeaways from Halozyme Therapeutics’s earnings call?
